Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $199.85, for a total value of $599,550.00. Following the completion of the transaction, the insider directly owned 150,023 shares of the company’s stock, valued at approximately $29,982,096.55. This trade represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The stock was sold at an average price of $230.77, for a total value of $378,232.03.
• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total value of $694,320.00.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total transaction of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92.

Natera Price Performance

NTRA stock opened at $207.04 on Wednesday. The company’s 50-day moving average is $225.25 and its 200-day moving average is $204.78. The stock has a market capitalization of $29.34 billion, a PE ratio of -135.32 and a beta of 1.65. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 16.71% and a negative net margin of 9.03%.During the same quarter in the prior year, the company earned ($0.41) earnings per share. On average, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Morgan Stanley decreased their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday. BTIG Research boosted their target price on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Guggenheim upped their target price on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Evercore lifted their price target on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, Piper Sandler boosted their price objective on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.47.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in NTRA. Integrated Wealth Concepts LLC lifted its position in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares during the last quarter. Focus Partners Wealth lifted its holdings in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after acquiring an additional 474 shares during the period. Sivia Capital Partners LLC bought a new stake in Natera during the second quarter worth $298,000. Finally, Envestnet Asset Management Inc. boosted its position in Natera by 5.9% in the second quarter. Envestnet Asset Management Inc. now owns 172,022 shares of the medical research company’s stock worth $29,061,000 after purchasing an additional 9,651 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.